CHICAGO--(BUSINESS WIRE)--Attune Medical will be attending the Heart Rhythm Society’s 2023 meeting to show the latest in proactive esophageal cooling and its ensoETM® temperature management technology. The company will be on the show’s exhibit floor at Booth 521 from May 19 through 21, and will host an informal meet-and-greet on May 20 at The Peacock Room at the Kimpton Hotel Fontenot from 5 to 7 p.m.
The annual Heart Rhythm meeting is the premier electrophysiology event, bringing together the largest gathering of heart rhythm professionals from around the world. The meeting will take place May 19 to 21 in New Orleans, LA.
The US FDA recently granted an Investigational Device Exemption (IDE) to Attune to evaluate the company’s ensoETM in the reduction of esophageal thermal injury during cardiac radiofrequency ablation procedures. Several published studies have examined the use of ensoETM for this purpose, including the IMPACT single-center study and the pilot eCOOL-AF study. Most recently, real-world data were published, and a large multi-center review of over 25,000 patients was completed.
Attune Medical’s ensoETM is a single use thermal regulating device that is placed in the esophagus (similar to a standard orogastric tube) and connected to an external heat exchange unit, creating a closed-loop system for heat transfer to increase or decrease patient temperature. Its placement in the esophagus, with proximity to blood flow from the heart and great vessels, allows highly efficient heat transfer. Unlike surface warming devices, ensoETM‘s internal placement doesn't impede patient access during surgery and allows gastric decompression and administration of fluids and medications.
Attune Medical’s novel medical device technology simplifies access to the patient’s core to efficiently control temperature and is the only device FDA-cleared for use in the esophagus for patient temperature management. The ensoETM device is used in critical care units, operating rooms, and emergency departments for the intentional modulation of patient core temperature and can be rapidly placed by most trained healthcare professionals.
The ensoETM has been cleared by the FDA to control patient temperature. The ensoETM has NOT been approved or cleared by the FDA to reduce thermal injury to the esophagus during radiofrequency cardiac ablation procedures.